Abstract 1695
Background
Both pertuzumab and T-DM1 improved overall survival (OS) of HER2+ metastatic breast cancer (MBC) in clinical trials. Little is known about their activity outside of clinical trials and when administered sequentially or after (neo)adjuvant pretreatment. Here we present real-word data from the MBC-Registry of the Austrian Study Group of Medical Tumor Therapy (AGMT).
Methods
The AGMT-MBC-Registry is a multicenter nationwide ongoing retrospective and prospective registry for MBC patients in Austria. Unadjusted, univariate survival probabilities of PFS and OS were calculated by the Kaplan-Meier method and compared by the log-rank test, multivariate hazard ratios (HR) were estimated by Cox regression models. In this analysis patients with known HER2 status and available survival data who received at least one palliative treatment line were included.
Results
As of 31/01/2019, 1262 patients were included in the AGMT-MBC-Registry. Out of 1090 evaluable patients, 256 (23.5%) were HER2+. Compared to patients with HER2- disease, HER2 positivity was significantly associated with longer OS (median OS 42.7 vs. 33.6 months; HR 0.80; 95%CI 0.67-0.96; P = 0.017). Patients treated with pertuzumab (106/256=41.4%) or T-DM1 (49/256=19.1%) had a significantly longer OS than patients who were not treated with these agents, respectively (HR 0.35; 95%CI 0.24-0.52; P < 0.001 and HR 0.48; 95%CI 0.31-0.75; P = 0.001). Furthermore, pertuzumab treatment was significantly associated with longer OS in multivariate analysis (P < 0.001). Median PFS of pertuzumab containing treatments was significantly longer when administered in first-line compared to later lines (23.7 vs. 6.3 months; HR 0.35; 95%CI 0.21-0.58; P < 0.001). In T-DM1 treated patients, median PFS of T-DM1 was longer when given in first- or second-line compared to later lines (11.0 vs. 8.4 months) and in pertuzumab naïve patients (11.0 vs. 7.6 months). However, these differences were not statistically significant.
Conclusions
Prognosis of HER2+ MBC has significantly improved by the implementation of pertuzumab and T-DM1 in this real-world population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Richard Greil.
Funding
Roche, Pfizer.
Disclosure
S.P.P. Gampenrieder: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Novartis; Speaker Bureau / Expert testimony: BMS; Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy: Eli Lilly; Travel / Accommodation / Expenses: Amgen; Travel / Accommodation / Expenses: Shire; Travel / Accommodation / Expenses: Bayer; Travel / Accommodation / Expenses: Celgene; Travel / Accommodation / Expenses: Daiichy Sankyo. G. Rinnerthaler: Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy: Celgene; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Speaker Bureau / Expert testimony: Lilly; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Amgen; Speaker Bureau / Expert testimony: AstraZeneca; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: BMS. A. Petzer: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Lilly; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche. D. Fuchs: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: AstraZeneca; Travel / Accommodation / Expenses: Tesa. M. Balic: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Amgen; Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Lilly; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: MSD; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony: Pierre Fabre; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy: Samsung; Speaker Bureau / Expert testimony, Research grant / Funding (self): Celgene; Travel / Accommodation / Expenses: BMS; Travel / Accommodation / Expenses: Boehringer Ingelheim. D. Egle: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Lilly; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca. A.F. Zabernigg: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer. C.F. Singer: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Novartis; Honoraria (self), Research grant / Funding (self), Travel / Accommodation / Expenses: Roche; Honoraria (self), Research grant / Funding (self), Travel / Accommodation / Expenses: Amgen; Honoraria (self), Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Pfizer. M. Hubalek: Honoraria (self): Pfizer; Honoraria (institution): AstraZeneca; Advisory / Consultancy: Novartis; Speaker Bureau / Expert testimony: Lilly; Research grant / Funding (self): Amgen; Travel / Accommodation / Expenses: Roche. R. Greil: Honoraria (self), Advisory / Consultancy: Daiichy Sankyo; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Roche; Honoraria (self), Research grant / Funding (self): Tarkeda; Honoraria (self), Research grant / Funding (self): Celgene; Honoraria (institution), Research grant / Funding (self): Novartis; Honoraria (self): BMS; Honoraria (self): Amgen. All other authors have declared no conflicts of interest.
Resources from the same session
3425 - Feasibility and impact of prospective DPYD screening in the Irish population
Presenter: Mohammed Zameer
Session: Poster Display session 2
Resources:
Abstract
1972 - Diet-derived metabolites and the risk of colorectal cancer: a nested case-control study in a population-based cohort, the Singapore Chinese Health Study
Presenter: Dawn Chong
Session: Poster Display session 2
Resources:
Abstract
4103 - Loss of subcutaneous adipose tissue during chemotherapy predicts reduced survival in patients with incurable colorectal cancer undergoing palliative therapy
Presenter: Erin Stella Sullivan
Session: Poster Display session 2
Resources:
Abstract
4309 - Obese and overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab.
Presenter: Bozena Cybulska-Stopa
Session: Poster Display session 2
Resources:
Abstract
3554 - Patient characteristics associated with poor performance status, ECOG 2-3, and effect on survival in 1086 Finnish metastatic colorectal cancers (mCRC) nationwide (prospective RAXO study)
Presenter: Pia Österlund
Session: Poster Display session 2
Resources:
Abstract
4572 - Discovery and Diagnosis of Metastatic Colorectal Cancer (mCRC) in the Real World: Final Results from a European Survey
Presenter: Iga Rawicka
Session: Poster Display session 2
Resources:
Abstract
4783 - Adherence to recommended intake of calcium and colorectal cancer risk in the HEXA study
Presenter: Jeeyoo Lee
Session: Poster Display session 2
Resources:
Abstract
5106 - Body size, sex and sidedness of incident colorectal cancer in a prospective Swedish cohort study
Presenter: Christina Siesing
Session: Poster Display session 2
Resources:
Abstract
3364 - Middle East & North Africa Registry to characterize RAS mutation status and tumor specifications in recently diagnosed patients with metastatic colorectal cancer (MORE-RAS Study)
Presenter: Mohamed Oukkal
Session: Poster Display session 2
Resources:
Abstract
3668 - Patient Demographics and Management Landscape of Metastatic Colorectal Cancer in the Third Line Setting: real-world data in an Australian Population
Presenter: Sandy Tun Min
Session: Poster Display session 2
Resources:
Abstract